PURPOSE OF REVIEW Redox regulation has been shown to be an important component of malignant cell survival and is a system that may be pharmacologically manipulated for the treatment of cancer. Motexafin gadolinium is a member of a class of rationally designed porphyrin-like molecules called texaphyrins. The rationale for its use in cancer therapy is that, like naturally occurring porphyrins, it tends to concentrate selectively in cancer cells and it has a novel mechanism of action as it induces redox stress, triggering apoptosis in a broad range of cancers. RECENT FINDINGS In vitro studies have shown that motexafin gadolinium is synergistic with radiation and varied chemotherapeutic agents. A phase III international study has shown that the onset of neurologic progression is significantly delayed in patients with brain metastases from lung cancer treated with whole-brain radiation and motexafin gadolinium (compared with radiation alone). Recent preclinical data have shown that motexafin gadolinium alone is cytotoxic to cancers such as multiple myeloma, non-Hodgkin lymphoma, and chronic lymphocytic leukemia through redox and apoptotic pathways. Multiple clinical trials examining motexafin gadolinium as a single agent and in combination with radiation and/or chemotherapy for the treatment of solid and hematopoietic tumors are underway. SUMMARY Motexafin gadolinium is a novel tumor-targeted agent that disrupts redox balance in cancer cells by futile redox cycling. Motexafin gadolinium is currently in numerous hematology/oncology clinical trials for use as a single agent and in combination with chemotherapy and/or radiation therapy.

中文翻译：

---

Motexafin lin：一种具有氧化还原活性的肿瘤选择剂，用于治疗癌症。

审查的目的氧化还原调节已被证明是恶性细胞存活的重要组成部分，并且是可以通过药理学方法治疗癌症的系统。Motexafin is是一类经过合理设计的类卟啉分子（称为texaphyrins）的成员。其在癌症治疗中使用的基本原理是，像天然存在的卟啉一样，它倾向于选择性地集中在癌细胞中，并且由于它诱导氧化还原应激，从而触发了广泛的癌症中的细胞凋亡，因此具有新颖的作用机制。最新发现体外研究表明，莫特沙芬g与放射线和多种化学治疗剂具有协同作用。一项国际III期研究表明，在接受全脑放射和莫他沙芬g治疗（与单独放射治疗相比）的肺癌脑转移患者中，神经系统疾病的发作明显延迟。最近的临床前数据表明，单独的莫达芬fin通过氧化还原和凋亡途径对多发性骨髓瘤，非霍奇金淋巴瘤和慢性淋巴细胞性白血病等癌症具有细胞毒性。目前正在进行多项临床试验，以莫托沙芬g作为单一药物，并与放射线和/或化学疗法联合治疗实体瘤和造血肿瘤。发明内容Motexafin is是一种新型的肿瘤靶向药物，可通过无效的氧化还原循环破坏癌细胞中的氧化还原平衡。